Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026

Bitget2026/09/30 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ocugen flagged upcoming presentations of clinical trial results for its modifier gene therapies in eye diseases.
Phase 2 ArMaDa trial readouts for OCU410 in geographic atrophy are scheduled for Oct. 9 and Oct. 11, 2026.
Management framed the ArMaDa update as covering safety and efficacy outcomes over 12 months, with no metrics disclosed.
Phase 1/2 GARDian1 results for OCU410ST in Stargardt disease will also be presented in early October 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300702PRIMZONEFULLFEED9836569) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026

You may also like

Crypto prices